BRIEF-Bayer says FDA rejects wider use of blood thinner Xarelto

FRANKFURT Fri Feb 14, 2014 8:16am EST

FRANKFURT Feb 14 (Reuters) - Bayer AG : * FDA Issues Complete Response Letters for Use of XARELTO (rivaroxaban) to Reduce the Risk of Secondary Cardiovascular Events and Stent Thrombosis in Patients with Acute Coronary Syndrome * Remains committed to providing patients who have suffered from acute coronary syndrome with additional protection against stent thrombosis and secondary life-threatening cardiovascular events

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.